The worlds first self-stabilising walking exoskeleton, Atlante X, has entered a rehabilitation trial in Germany.
Atalante Xs efficacy will be compared with standard rehabilitation methods.
Both clinics will this month begin recruiting a total of 66 patients.
40% off TNW Conference!
Its opening proposal, Atalante, was launched in 2019.
Wandercraft believesit was the first bipedal walking robot to become a full commercial product.
Atalante X is the second iteration of the tool.
Using a proprietary self-balancing feature,the exoskeleton provides hands-free andmulti-directional locomotion.
Therapists can use the gadget to personalise task-orientated treatments for each patients needs.
Regulators have shown growing faith in the system.
In January, the US Food and Drug Administration (FDA)clearedAtalante for use in stroke rehabilitation.
Investors have also provided strong support, ploughing a total of around $67mn (63mn) into Wandercraft.
The trial in Germany provides another opportunity to develop the product.
The German launch expands Wandercrafts strong commercial presence inEurope, which also includes footholds in France and Spain.
The company is now targeting the biggest market of them all: the USA.
Story byThomas Macaulay
Thomas is the managing editor of TNW.
He leads our coverage of European tech and oversees our talented team of writers.
Away from work, he e(show all)Thomas is the managing editor of TNW.
He leads our coverage of European tech and oversees our talented team of writers.
Away from work, he enjoys playing chess (badly) and the guitar (even worse).
